The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Trial of Spesolimab for Generalized Pustular Psoriasis
Open accessAbstract
BACKGROUND: Generalized pustular psoriasis (GPP) is a rare, life-threatening, inflammatory skin disease characterized by widespread eruption of sterile pustules. Interleukin-36 signaling is involved in the pathogenesis of this disorder. Spesolimab, a humanized anti-interleukin-36 receptor monoclonal antibody, is being studied for the treatment of GPP flares. METHODS: In a phase 2 trial, we randomly assigned patients with a GPP flare in a 2:1 ratio to receive a single 900-mg intravenous dose of spesolimab or placebo. Patients in both groups could receive an open-label dose of spesolimab on day 8, an open-label dose of spesolimab as a rescue medication after day 8, or both and were followed to week 12. The primary end point was a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of 0 (range, 0 [no visible pustules] to 4 [severe pustulation]) at the end of week 1. The key secondary end point was a GPPGA total score of 0 or 1 (clear or almost clear skin) at the end of week 1; scores range from 0 to 4, with higher scores indicating greater disease severity. RESULTS: A total of 53 patients were enrolled: 35 were assigned to receive spesolimab and 18 to receive placebo. At baseline, 46% of the patients in the spesolimab group and 39% of those in the placebo group had a GPPGA pustulation subscore of 3, and 37% and 33%, respectively, had a pustulation subscore of 4. At the end of week 1, a total of 19 of 35 patients (54%) in the spesolimab group had a pustulation subscore of 0, as compared with 1 of 18 patients (6%) in the placebo group (difference, 49 percentage points; 95% confidence interval [CI], 21 to 67; P<0.001). A total of 15 of 35 patients (43%) had a GPPGA total score of 0 or 1, as compared with 2 of 18 patients (11%) in the placebo group (difference, 32 percentage points; 95% CI, 2 to 53; P = 0.02). Drug reactions were reported in 2 patients who received spesolimab, in 1 of them concurrently with a drug-induced hepatic injury. Among patients assigned to the spesolimab group, infections occurred in 6 of 35 (17%) through the first week; among patients who received spesolimab at any time in the trial, infections had occurred in 24 of 51 (47%) at week 12. Antidrug antibodies were detected in 23 of 50 patients (46%) who received at least one dose of spesolimab. CONCLUSIONS: In a phase 2 randomized trial involving patients with GPP, the interleukin-36 receptor inhibitor spesolimab resulted in a higher incidence of lesion clearance at 1 week than placebo but was associated with infections and systemic drug reactions. Longer and larger trials are warranted to determine the effect and risks of spesolimab in patients with pustular psoriasis. (Funded by Boehringer Ingelheim; Effisayil 1 ClinicalTrials.gov number, NCT03782792.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kardaun, S. H., Sekula, P., Valeyrie-Allanore, L., Liss, Y., Chu, C. Y., Creamer, D., Sidoroff, A., Naldi, L., Mockenhaupt, M., Roujeau, J. C., et al. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12501 · Cited by 1,010
Interleukin-36–Receptor Antagonist Deficiency and Generalized Pustular Psoriasis
Marrakchi, S., Guigue, P., Renshaw, B. R., Puel, A., Pei, X.-Y., Fraitag, S., Zribi, J., Bal, E., Cluzeau, C., Chrabieh, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013068 · Cited by 998
Self-citationEuropean consensus statement on phenotypes of pustular psoriasis
Navarini, A. A., Burden, A. D., Capon, F., Mrowietz, U., Puig, L., Köks, S., Kingo, K., Smith, C., Barker, J. N., & the ERASPEN Network (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14386 · Cited by 450
Self-citationInhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis
Bachelez, H., Choon, S.-E., Marrakchi, S., Burden, A. D., Tsai, T.-F., Morita, A., Turki, H., Hall, D. B., Shear, M., Baum, P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1811317 · Cited by 292
Self-citationTest‐Based Exact Confidence Intervals for the Difference of Two Binomial Proportions
Chan, I. S. F., & Zhang, Z. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.01202.x · Cited by 291
Fujita, H., Terui, T., Hayama, K., Akiyama, M., Ikeda, S., Mabuchi, T., Ozawa, A., Kanekura, T., Kurosawa, M., Komine, M., et al. (2018) · The Journal of Dermatology · doi:10.1111/1346-8138.14523 · Cited by 254
Exact Unconditional Sample Sizes for the 2 × 2 Binomial Trial
Suissa, S., & Shuster, J. J. (1985) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2981892 · Cited by 234
AP1S3 Mutations Are Associated with Pustular Psoriasis and Impaired Toll-like Receptor 3 Trafficking
Setta-Kaffetzi, N., Simpson, M. A., Navarini, A. A., Patel, V. M., Lu, H.-C., Allen, M. H., Duckworth, M., Bachelez, H., Burden, A. D., Choon, S.-E., et al. (2014) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2014.04.005 · Cited by 186
Self-citationGeneralized pustular psoriasis (Zumbusch): a French epidemiological survey.
Augey, F., Renaudier, P., & Nicolas, J. (2006) · PubMed · Cited by 144
Multiplicity Considerations in Clinical Trials
Dmitrienko, A., & D’Agostino, R. B. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1709701 · Cited by 140
Cited by
Signaling pathways and targeted therapies for psoriasis
Guo, J., Zhang, H., Lin, W., Lu, L., Su, J., & Chen, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01655-6 · Cited by 427
Kaplon, H., Crescioli, S., Chenoweth, A., Visweswaraiah, J., & Reichert, J. M. (2023) · mAbs · doi:10.1080/19420862.2022.2153410 · Cited by 273
Immune modules to guide diagnosis and personalized treatment of inflammatory skin diseases
Seremet, T., Di Domizio, J., Girardin, A., Yatim, A., Jenelten, R., Messina, F., Saidoune, F., Schlapbach, C., Bogiatzi, S., Minisini, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54559-6 · Cited by 57
Mou, R., Ma, J., Ju, X., Wu, Y., Chen, Q., Li, J., Shang, T., Chen, S., Yang, Y., Li, Y., et al. (2024) · Cell Stem Cell · doi:10.1016/j.stem.2024.09.018 · Cited by 20
Metadata
- Authors
- Bachelez, H., Choon, S.-E., Marrakchi, S., Burden, A. D., Tsai, T.-F., Morita, A., Navarini, A. A., Zheng, M., Xu, J., Turki, H., Anadkat, M. J., Rajeswari, S., Hua, H., Vulcu, S. D., Hall, D., Tetzlaff, K., Thoma, C., & Lebwohl, M. G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-12-23
- Volume
- 385
- Issue
- 26
- Pages
- 2431-2440
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4200421636
- Cited by
- 356
- References
- 19
- FWCI
- 16.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Trial of Spesolimab for Generalized Pustular Psoriasis. https://app.cochat.ai/papers/10.1056/nejmoa2111563
- The paper
- Bachelez, H., Choon, S.-E., Marrakchi, S., Burden, A. D., Tsai, T.-F., Morita, A., Navarini, A. A., Zheng, M., Xu, J., Turki, H., Anadkat, M. J., Rajeswari, S., Hua, H., Vulcu, S. D., Hall, D., Tetzlaff, K., Thoma, C., & Lebwohl, M. G. (2021). Trial of Spesolimab for Generalized Pustular Psoriasis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2111563
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.